Angiotensin II Medicine 13 December 2018 Extended indication Hypotension in adults with septic or other distributive shock Therapeutic value No judgement Total cost Registration phase Registration application pending Product Active substance Angiotensin II Domain Cardiovascular diseases Reason of inclusion New medicine (specialité) Main indication Other medication for cardiovascular diseases Extended indication Hypotension in adults with septic or other distributive shock Current proprietary name Already available biosimilars / generics Proprietary name Giapreza Manufacturer La Jolla Portfolio holder Mechanism of action Unknown Route of administration Intravenous Therapeutical formulation Intravenous drip Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks Angiotensin-type-1-receptor-agonists Registration Registration route Centralised (EMA) Type of trajectory Normal trajectory Particularity Unknown ATMP Unknown Submission date July 2018 Expected Registration August 2019 Orphan drug No Registration phase Registration application pending Reimbursement Medicine sluice Additional remarks In Juli op de lijst van de EMA (Medicines Under Evaluation). Therapeutic value Current treatment options Therapeutic value No judgement This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration Dosage per administration starten met 20 ng/ kg/min voor 3 uur References Additional remarks Expected patient volume per year Patient volume < 15,000 Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References SPS Additional remarks In Amerika 300.000 personen die in aanmerking zouden komen voor het geneesmiddel, teruggerekend naar Nederland zou dat gaan 15.000 patiënten. Expected cost per patient per year Cost References Additional remarks Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions Unknown Indication extensions References Additional remarks Other information Additional remarks